Form 4: Bolt Biotherapeutics COO Reprices Stock Options

Sentiment:

Insider Transaction Report 16 December 2025 5:11 PM

📋All filings for Bolt Biotherapeutics, INC

Bolt Biotherapeutics' Chief Operating Officer, Grant Yonehiro, exchanged multiple high-priced stock options for new options with a significantly lower exercise price of $5.44 per share.

Worse than expectedThe original exercise prices for the cancelled options ranged from $7.02 to $400, while the new exercise price is $5.44. This indicates a substantial decline in the company's stock price over time, rendering the previous options out-of-the-money and ineffective as incentives.The repricing itself, while beneficial to the executive, reflects a past poor performance of the company's stock.

Summary

Grant Yonehiro, Chief Operating Officer of Bolt Biotherapeutics, Inc., engaged in a series of derivative security transactions on December 12, 2025.
Multiple existing employee stock options, originally granted between January 2017 and May 2025, with exercise prices ranging from $7.02 to $400, were cancelled.
Concurrently, new employee stock options were granted for a total of 75,928 underlying shares of common stock, all with a uniform exercise price of $5.44 per share.
The new options replace the cancelled ones, effectively repricing the executive's equity incentives at a significantly lower valuation.
Some of the newly granted options have specific vesting schedules, requiring continuous service to the Issuer, with vesting occurring monthly over 36 months following various start dates (e.g., January 1, 2023, January 1, 2024, July 15, 2024, and January 1, 2025).

Sentiment

Score: 3

Explanation: The repricing of options, while beneficial for executive retention and motivation, fundamentally signals a significant decline in the company's stock value, which is a negative indicator for overall company performance and investor sentiment.

Positives

The Chief Operating Officer received new stock options with a significantly lower exercise price of $5.44, making them more likely to be in-the-money and provide value as an incentive.
This repricing could serve as a crucial mechanism for management retention and motivation, aligning the executive's interests with future stock price recovery after a period of decline.

Negatives

The necessity for option repricing indicates a substantial decline in Bolt Biotherapeutics' stock price, as the original options were significantly out-of-the-money with exercise prices up to $400.
The repricing could be viewed negatively by existing shareholders as it effectively resets management's equity incentives at a lower valuation, potentially diluting future shareholder value if the stock recovers.

Risks

Shareholder Dilution: If the stock price recovers and these lower-priced options are exercised, it could lead to dilution for existing shareholders.
Perception of Poor Performance: The repricing of options often signals to the market that the company's stock has performed poorly, potentially impacting investor confidence and future valuation.
Executive Retention Risk (Mitigated): The original high-priced options likely offered little incentive, posing a retention risk for key executives, which this repricing aims to mitigate, but the underlying issue of poor stock performance remains.

Future Outlook

Industry Context

The repricing of executive stock options is a common practice in industries, particularly biotechnology, where stock prices can be highly volatile due to long development cycles, clinical trial results, and market sentiment. Such actions aim to re-incentivize management and retain key talent in challenging market conditions where original equity grants may have become significantly out-of-the-money.

Comparison to Industry Standards

Option repricing is a known mechanism used by companies, especially in volatile sectors like biotech, to retain and motivate key executives when stock prices have fallen significantly below original grant prices.
Companies like Moderna (MRNA) or BioNTech (BNTX), while not directly comparable in terms of specific repricing events, operate in an industry where stock performance can be highly sensitive to clinical trial results and market sentiment, often leading to situations where executive compensation structures need adjustment to remain effective.
The practice is generally viewed with mixed sentiment; while it can be crucial for retention, it can also be seen as detrimental to shareholder value if not managed transparently and justified by clear performance objectives.

Stakeholder Impact

Shareholders: Potential for future dilution if the stock price recovers and the lower-priced options are exercised. May also signal past poor stock performance and raise questions about executive compensation practices.
Employees (Executive): Increased incentive and motivation for the Chief Operating Officer due to more favorable option pricing, potentially aiding retention and aligning interests with future company growth.

Next Steps

The newly granted options will vest according to their respective schedules, contingent on the Chief Operating Officer's continuous service to the Issuer.
The Chief Operating Officer may exercise these options in the future if the stock price rises above the $5.44 exercise price.

Key Dates

Date	Description
2017-01-18	Original grant date of an option for 3,214 shares, later cancelled.
2018-01-17	Original grant date of an option for 660 shares, later cancelled.
2018-04-04	Original grant date of an option for 822 shares, later cancelled.
2019-01-11	Original grant date of an option for 1,653 shares, later cancelled.
2019-11-13	Original grant date of an option for 4,642 shares, later cancelled.
2020-09-03	Original grant date of an option for 2,142 shares, later cancelled.
2021-02-04	Original grant date of an option for 4,999 shares, later cancelled.
2022-02-18	Original grant date of an option for 9,499 shares, later cancelled.
2023-01-01	Start date for vesting schedule of an option for 11,399 shares (1/36th per month).
2023-02-27	Original grant date of an option for 11,399 shares, later cancelled.
2024-01-01	Start date for vesting schedule of an option for 11,749 shares (1/36th per month).
2024-03-04	Original grant date of an option for 11,749 shares, later cancelled.
2024-07-15	Start date for vesting schedule of an option for 7,749 shares (1/36th per month).
2024-07-23	Original grant date of an option for 7,749 shares, later cancelled.
2025-01-01	Start date for vesting schedule of an option for 17,499 shares (1/36th per month).
2025-05-01	Original grant date of an option for 17,499 shares, later cancelled.
2025-12-12	Date of option cancellation and re-grant transactions.
2025-12-16	Date the Form 4 was signed by Attorney-in-Fact.
2027-01-17	Expiration date for options related to 3,214 shares.
2028-01-16	Expiration date for options related to 660 shares.
2028-04-03	Expiration date for options related to 822 shares.
2029-01-10	Expiration date for options related to 1,653 shares.
2029-11-12	Expiration date for options related to 4,642 shares.
2030-09-02	Expiration date for options related to 2,142 shares.
2031-02-03	Expiration date for options related to 4,999 shares.
2032-02-17	Expiration date for options related to 9,499 shares.
2033-02-26	Expiration date for options related to 11,399 shares.
2034-03-03	Expiration date for options related to 11,749 shares.
2034-07-22	Expiration date for options related to 7,749 shares.
2035-04-30	Expiration date for options related to 17,499 shares.

Recommendation

hold

The repricing of executive stock options, while a common practice to re-incentivize management after a significant stock price decline, inherently signals past underperformance. The new lower exercise price makes the options more valuable to the executive, potentially aiding retention, but also implies a substantial drop from previous valuations. Investors should 'hold' to observe if this renewed incentive translates into improved company performance and stock recovery, as the underlying reason for the repricing is a negative indicator, but the action itself aims to stabilize executive motivation. Further financial and operational updates are needed to assess the company's future trajectory.

Keywords

Bolt Biotherapeutics, BOLT, SEC Form 4, Stock Options, Option Repricing, Executive Compensation, Grant Yonehiro, Chief Operating Officer, Equity Incentive, Dilution

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.